Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)

ROCKET AF Steering Committee and Investigators, Sameer Bansilal, Zachary Bloomgarden, Jonathan L Halperin, Anne S Hellkamp, Yuliya Lokhnygina, Manesh R Patel, Richard C Becker, Günter Breithardt, Werner Hacke, Graeme J Hankey, Christopher C Nessel, Daniel E Singer, Scott D Berkowitz, Jonathan P Piccini, Kenneth W Mahaffey, Keith A A Fox

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)'. Together they form a unique fingerprint.

Medicine & Life Sciences